Definium Therapeutics, Inc. (DFTX)
NMS · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
DFTX advances DT120 ODT trials, targeting NDA with three clinical readouts
# 📋 What This Document Is 🚀 This filing is an 8-K, which is a highly important filing used by companies to quickly announce major, unscheduled corporate events. This specific filing is related to an Investor and Analyst Day, meaning it serves as a deep dive into Definium Therapeutics' (DFTX) prog
SEC filings
All filings →Insider trades
All insider trades →Definium Therapeutics, Inc. has no reported insider trades in the last 90 days.